Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05297903 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

XmAb20717 in Advanced Biliary Tract Cancers

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Primary completion date changed from estimate of Dec 2, 2026 to Jul 13, 2026 · Eligibility criteria expanded, about 29 words Show 2 more changesShow less
    • Primary completion date changed from estimate of Dec 2, 2026 to Jul 13, 2026
    • Eligibility criteria expanded, about 29 words
  2. Re-verified, no change to tracked fieldsv8
  3. Primary and study completion dates: Dec 31, 2024 to Dec 2, 2026v7
  4. Primary completion date: Mar 31, 2024 to Dec 31, 2024v6
  5. Trial status: Recruiting to Active, Not Recruiting Site details revisedv5 Show 1 more changeShow less
    • Site details revised
Show 3 earlier versionsHide 3 earlier versions
  1. Eligibility criteria expanded, about 438 words Secondary endpoints: 2 to 4v4 Show 1 more changeShow less
    • Secondary endpoints: 2 to 4

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Mar 15, 2022 to Apr 11, 2022 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Mar 15, 2022 to Apr 11, 2022
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-arm, phase II clinical trial to evaluate the efficacy of XmAb20717 in patients with advanced biliary tract cancers who have progressed on, or were intolerant of, a gemcitabine-based chemotherapy regimen.
Trial Details
NCT Number NCT05297903
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Xencor, Inc.
Conditions Biliary Tract Cancer
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov